The dual approach, though rare, was linked to fewer 2-year MACE and lower long-term costs compared with angiography alone.
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield® and PainShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results